Business Wire

SAMSUNG-SEMICONDUCTOR

15.9.2020 11:02:12 CEST | Business Wire | Press release

Share
Samsung Expands Advanced 0.7μm-Pixel ISOCELL Image Sensor Offerings for Wider Mobile Applications

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced four new Samsung ISOCELL image sensors for its 0.7 micrometer (μm)-pixel product lineup; 108-megapixel (Mp) ISOCELL HM2, 64Mp ISOCELL GW3, 48Mp ISOCELL GM5 and 32Mp ISOCELL JD1. With the new 0.7μm ISOCELL technology, Samsung plans to expand the ultra-high-resolution offerings to mainstream smartphones.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005521/en/

“Samsung continues to pioneer innovations, such as ISOCELL Plus and Smart ISO, to deliver more pixels in a smaller package,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “Last year, Samsung introduced the industry’s first 0.7μm-pixel image sensor and the first 108Mp sensors. Now we are bringing more of the advanced pixel technologies to mobile cameras in a variety of options that will enable high-resolution images and sleeker designs in a wider selection of tomorrow’s mobile devices.”

For ultra-high-resolution image sensors, even a mere 0.1μm-difference per pixel can have a significant impact on the overall size of the sensor as well as the height of the camera module. With pixels at 0.7μm, Samsung’s newest image sensors are up to 15-percent smaller than the 0.8μm sensors of the same resolution and reduce the height of the camera module by up to 10 percent. Smaller form factors give smartphone manufacturers more flexibility, such as added features or more streamlined designs, when developing their next-generation devices.

To collect an ample amount of light and increase the full well capacity despite the minute pixel sizes, Samsung has incorporated its advanced ISOCELL Plus and Smart-ISO technologies, especially optimized for 0.7μm. ISOCELL Plus retains the received light with a wall-like structure around the pixel while Smart-ISO makes full use of the incoming light by intelligently adjusting the ISO accordingly for optimal exposure.

In the latest 0.7μm products to be introduced later this year, Samsung will start rolling out an enhanced pixel technology, ISOCELL 2.0, which allows excellent performance despite the challenges with decreasing pixel sizes. The new technology further enhanced the wall structure between cells, resulting in added light sensitivity of up to 12 percent compared to the current ISOCELL Plus technology.

The New 0.7μm Lineup;

  1. ISOCELL HM2 is Samsung’s third 108Mp image sensor following the HMX and HM1. The new 108Mp-sensor is around 15-percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent. The HM2 features Super PD, a faster and more effective phase detecting auto focus solution, and like the HM1, comes with a nine-pixel binning technology as well as 3x lossless zoom.
  2. ISOCELL GW3 is a 64Mp-image sensor optimized for mainstream devices. Thanks to the smaller pixel size, the GW3’s optical size is nearly identical to that of Samsung’s 0.8μm 48Mp image sensor. In addition to Tetracell and Smart-ISO technologies that help the sensor take bright images with high color fidelity, the GW3 is ideal for active lifestyles, featuring gyro-based electronic image stabilization (EIS) for sharper still photos and steadier videos. The image sensor supports video recording at up to 4K resolution at 60 frames-per-second (fps).
  3. ISOCELL GM5 is a versatile 48Mp-image sensor designed for use in telescoping or ultra-wide angle cameras. When used as a 5x optical telescoping sensor for folded-zoom, the GM5 takes full advantage of the compact 0.7μm pixel size that minimizes the camera bulge. For ultra-wide shots, the GM5 supports high-speed full-HD recording at 480fps. The sensor also offers a staggered-HDR feature, a faster and more power-efficient HDR technology that expedites image processing by sending a readout of long, medium, and short exposures of each row of pixels respectively to the mobile processor. As the readout is performed based on Tetracell’s 1.4μm two-by-two pixels, rather than at the individual 0.7μm-pixel level, staggered-HDR can provide brighter and clearer images with less noise.
  4. ISOCELL JD1 is the industry’s smallest 32Mp-image sensor at 1/3.14-inches, making it an ideal solution for smartphones with bezel-less displays that incorporate a hole-in-active-area or motorized pop-up mechanism for the front-facing camera. Even with 32-million pixels to capture a highly detailed selfie, the camera sits comfortably under the display as the height of the sensor’s camera module is comparable to those of 0.9μm 20Mp or 1.0μm 16Mp sensors. Like the GM5, the JD1 is also the one the first ISOCELL image sensors to offer staggered-HDR.

Samsung ISOCELL HM2, GW3 and JD1 are currently in mass production, and the company is sampling GM5.

# # #

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

# # #

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye